Starting from "Life-Related Industry"── reading the walls between us and patients, from multiple vantage points

01The weight of "life-related industry"

"Life-related industry" — pharma, medical devices, food, cosmetics, agrochemicals. All make things that enter or touch the human body. The common feature: "the place where the product functions is inside a human body".

Ordinary industries (cars, appliances, IT services) — when the product fails, at worst you replace it. Life-related industries — when the product fails, a human is broken. That asymmetry is the starting point of pharma compliance.

"Pharmaceuticals are not bicycles." — a phrase former FDA officials liked to use when discussing regulation and ethics. A drug already on the market cannot be casually fixed by a recall.

02The 1st wall — information

The first wall between us and patients is "information asymmetry".

• The company knows everything — mechanism of action, raw clinical trial data, adverse-event information, competitor data
• The patient receives only fragments — the package insert, the physician's explanation, the company's promotional material
• Even healthcare professionals cannot see the whole of the company's internal data

This wall is technically and structurally unavoidable. The question is "how we treat its existence".

Honest treatment: do not exploit the gap; disclose, in understandable form, what patients and HCPs need for their decisions.
Dishonest treatment: exploit the gap to get the audience to interpret things favorably to the company. This is the root of regulatory violation (exaggerated advertising).

03The 2nd wall — institution

The second wall is "institutional distance". Pharma operates inside laws (the Pharmaceutical Act, GxP, the insurance system, the Medical Care Act). Patients receive drugs without knowing those institutions:

• "This drug was approved" = what level of evidence was accumulated
• "Efficacy" = the legally-permitted scope of claim
• "Adverse event reporting" = statistical data submitted to the government
• "Prescription drug" = why a physician's prescription is required

Between the language of institutions and the patient's sensibility — "cure", "works", "safe" — lies a deep gap. Pharma employees are trained to think in institutional terms; patients are not. This matters for patient-rights protection (see Ethics Vol. 2).

04The 3rd wall — economics

The third wall is "the money flow".

For a pharma employee, "high drug price" is the precondition for continued research investment; for a patient, it can be the reason to stop treatment. To the same price on the same drug, the two sides assign opposite meanings.

Speaking of "wonderful new drug" without this economic wall in view causes "the reality of patients who cannot obtain that drug" to drop out of view. That is a way of speaking that chips away at industry trust, one chip at a time.

05The 4th wall — time

The fourth wall is "the difference in time scales".

Pharma is "trained to think on long time scales". The patient lives "in pain now, in fear now". The same word "new drug" resonates in completely different temporal senses for the two sides.

06The 5th wall — psychology

The fifth, and the hardest to see, is "the psychology of position":

• Pharma employees are trained to judge as "professionals", screening out emotion
• Patients live as "the one with the disease", unable to detach from emotion
• Pharma employees rarely see the patient as a "person" (internally, most see patients as "cases" or "market size")
• Patients see the pharma company as "a faceless giant organization"

This psychological wall surfaces with every industry scandal. Diovan, the HIV-tainted blood disaster, Thalidomide — events that in retrospect make one say "how could they not notice" often trace back to "the lack of a regular circuit in daily work for seeing the patient as an individual".

07For whose sake do the five walls exist?

We've seen the five walls. Information, institution, economics, time, psychology. These are structures that exist unavoidably. No effort by pharma personnel can fully erase them.

What we can do, then: "be aware of the walls' existence and refuse to exploit them".

• Information wall → Say "I don't know" when you don't. Don't give explanations that mislead
• Institutional wall → Explain in words patients understand. Don't hide behind jargon
• Economic wall → Consider drug-price discussions in the context of treatment continuity for patients
• Time wall → Tell honestly "this can't be done immediately". Don't sell hope
• Psychological wall → Regularly imagine the individual patients "on the other side" of your work

08Connection to other chapters ── ethics, drug-disaster history, regulation

The five walls covered here share a consistent worldview with other chapters on this site.

• Ethics Vol. 2 — How should pharma behave when patient rights are read from the stakeholder seat. The "psychological wall" connects directly here
• Ethics Vol. 3 — The Nuremberg-to-Helsinki history is precisely the record of what happens when these five walls are exploited. "Not forgetting history" is the only way to prevent that exploitation
• Drug Disaster History — Thalidomide, HIV blood disaster, Vioxx — all are cases of compound exploitation of the five walls. History is the teacher
• Ad Regulations + Material Review — The five-layer regulatory net is the institutional answer to prevent the walls' exploitation. The text rests on the existence of these walls

09The pride of being "life-related"

The talk of the five walls may at first sound to pharma personnel like "heavy responsibility". It is heavy.

But invert the view, and this also says "our work handles something that important". People making cars, appliances, IT services do worthy work. But pharma is among the few industries that "makes products that enter the human body, carrying human trust on its shoulders".

Bearing both the pride and the responsibility — that is what it means to work in life-related industry. Compliance is the practical ethic for protecting that pride.